Novo Nordisk’s Wegovy head start on pills forces investors to rethink Eli Lilly's GLP-1 dominance

Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.

from International: Top News And Analysis https://ift.tt/2WNOQHM